Declaration of competing interest Possible conflicts of interest over the last 3-years. GS: Dr. Sanacora has served as consultant to Ancora, Aptinyx, Atai, Axsome Therapeutics, Biogen, Biohaven Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Clexio, Cowen, Denovo Biopharma, ECR1, EMA Wellness, Engrail Therapeutics, Freedom Biosciences, Gilgamesh, Intra-Cellular Therapies, Janssen, KOA Health, Levo therapeutics, Lundbeck, Merck, MiCure, Navitor Pharmaceuticals, Neurocrine, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Relmada Therapeutics, Sage Pharmaceuticals, Seelos Pharmaceuticals, Taisho Pharmaceuticals, Usona Institute, Valeant, Vistagen Therapeutics, and XW Labs; and received research contracts from Johnson & Johnson/Janssen, Merck, and the Usona Institute over the past 36 months. Dr. Sanacora holds equity in Biohaven Pharmaceuticals, Freedom Biosciences, Gilead, Relmada, and Tetricus. He is a co-inventor on a US patent (#8778,979) held by Yale University and a co-inventor on US Provisional Patent Application No 047,162–7177P1 (00,754) filed on August 20, 2018, by Yale University Office of Cooperative Research. Yale University has a financial relationship with Janssen Pharmaceuticals and may receive financial benefits from this relationship. The University has put multiple measures in place to mitigate this institutional conflict of interest. Questions about the details of these measures should be directed to Yale University's Conflict of Interest office. BSB: Dr Barnett has advisory/consulting relationships with CB Therapeutics, Compass Pathways, Cerebral, Dynamed, Janssen Pharmaceuticals, and Livanova. He has received research funding for the conduct of clinical trials (administered through Cleveland Clinic) from MindMed and Compass Pathways. BH: No conflicts of interest. FSG: No conflicts of interest. SJM:Dr. Mathew has received consultant fees or research support from Abbott, Almatica Pharma, Autobahn Therapeutics, Biohaven, BioXcel Therapeutics, Boehringer-Ingelheim, Brii Biosciences, Clexio Biosciences, COMPASS Pathways, Delix Therapeutics, Douglas Pharmaceuticals, Engrail Therapeutics, Freedom Biosciences, Liva Nova, Levo Therapeutics, Merck, Motif Neurotech, Neumora, Neurocrine, Perception Neurosciences, Praxis Precision Medicines, Relmada Therapeutics, Sage Therapeutics, Seelos Therapeutics, Signant Health, Sunovion Pharmaceuticals, Xenon Pharmaceuticals, Worldwide Clinical Trials, and XW Pharma. JWM: Dr. Murrough has provided consultation services for Biohaven Pharmaceuticals, Inc., Cliniclabs, Inc., Clexio Biosciences, Ltd., Compass Pathfinder, Plc., Engrail Therapeutics, Inc., Janssen Pharmaceuticals, KetaMed, Inc., LivaNova, Plc., Merck & Co., Inc., Otsuka Pharmaceutical, Ltd., Sage Therapeutics, WCG, and Xenon Pharmaceuticals, Inc. The Icahn School of Medicine (employer of Dr. Murrough) is named on a patent and has entered into a licensing agreement and will receive payments related to the use of ketamine or esketamine for the treatment of depression. The Icahn School of Medicine is also named on a patent related to the use of ketamine for the treatment of PTSD. Dr. Murrough is not named on these patents and will not receive any payments. IR: No conflicts of interest. STW: Dr. Wilkinson has received contract research funding for the conduct of clinical trials (administered through Yale University) from Janssen and Oui Therapeutics. He has received consulting fees from LivaNova and Sage Therapeutics. AA: No conflicts of interest.
PubMed
